INBIOGEN Q1 2026 Loss Widens to 14.6B KRW
인바이오젠
101140
Signal Score
Historical Avg Return (5d)
-0.18%
Data Coverage
100%n=3385
Risk-adjusted indicator based on 3385 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Q1 2026 Revenue: 786.28M KRW
- • Q1 2026 Operating Loss: 979.67M KRW
- • Q1 2026 Net Loss: 14.68B KRW
- • Q1 2026 Debt-to-Equity Ratio: 3.75%
- • Common Shares Outstanding: 10,044,216 Shares
AI Analysis Summary
INBIOGEN CO.,Ltd reported a significant widening of its net loss to 14.68 billion KRW in Q1 2026, compared to a net loss of 1.42 billion KRW in FY 2025 and a net profit of 16.12 billion KRW in FY 2024. Revenue for Q1 2026 was 786.28 million KRW, with an operating loss of 979.67 million KRW. The company's debt-to-equity ratio increased to 3.75% from 1.49% at the end of 2025. The primary business segments are Kiosk (87.35% of revenue) and F&B (12.65%). The substantial increase in net loss and debt-to-equity ratio indicates deteriorating financial health, posing a negative outlook for investors.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.